Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Beijing Kejing Biotechnology Co., Ltd.
M.D. Anderson Cancer Center
Southwest Hospital, China
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham